SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Pharma News Only (pfe,mrk,wla, sgp, ahp, bmy, lly)
PFE 25.87+0.7%11:11 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Anthony Wong who wrote (1507)3/12/1999 10:56:00 PM
From: Anthony Wong   of 1722
 
FDA Grants Priority Review To Actos For Treatment Of Type II Diabetes

PRINCETON, NJ -- March 12, 1999 -- The United States Food and Drug
Administration has granted priority review status to Takeda America Research and
Development Center, Inc.'s Actos(TM) (pioglitazone hydrochloride) tablets, an
investigational agent for the treatment of type II diabetes.

Studied in more than 2,500 patients in the United States to date, Actos is a member of
the newest class of diabetes treatments, insulin-sensitising agents called
thiazolidinediones. Insulin sensitisers help restore the body's ability to effectively use its
own insulin by reducing insulin resistance -- a defect that has been identified as a
possible cause of type II diabetes.

Diabetes affects the body's ability to produce or respond properly to insulin, a
hormone that allows blood sugar to enter the cells of the body and be used for energy.
Type II diabetes, formerly known as non-insulin-dependent diabetes, is the most
common type of diabetes, affecting about 15 million Americans. It usually occurs in
people over age 45. Left untreated, diabetes can lead to serious health complications,
including blindness, amputation, kidney failures and heart attacks. All told, diabetes
consumes $98 billion US in U.S. health care costs annually.

Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News